Plexiform Biosciences develops PB-01, a pioneering eye drop formula designed to treat retinal vascular diseases non-invasively. This engineered solution delivers targeted treatment directly to the retina, offering an alternative to frequent intravitreal injections. The company focuses on making retinal condition treatment simpler, more accessible, and patient-centered.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for retinal vascular diseases often require frequent intravitreal injections, which can be uncomfortable for patients and create barriers to access, leading to potential delays in care and vision loss. Millions of individuals with retinal conditions lack effective, non-invasive treatment options.
Solution
Plexiform Biosciences is developing PB-01, an engineered eye drop formula designed to deliver targeted therapies directly to the retina, offering a non-invasive alternative to injections. This approach aims to simplify the treatment process, improve patient comfort, and enhance accessibility to retinal care. By making eye drops a first-line treatment option, Plexiform Biosciences seeks to address the unmet needs of individuals with retinal vascular diseases and improve overall outcomes. The company's focus is on innovating patient-centered solutions to make eye health simpler and more accessible for everyone.
Target Audience
The primary target audience includes individuals suffering from retinal vascular diseases and the ophthalmologists and retinal specialists who treat them.
Features
- PB-01: An engineered eye drop formula for targeted retinal treatment.
- Non-invasive approach eliminates the need for intravitreal injections.
- Designed to treat retinal vascular diseases.